System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Masakazu Toi

Oncology — Tokyo Metropolitan Komagome Hospital, Japan

LeadR Profile

Masakazu Toi Tokyo Metropolitan Komagome Hospital Japan
3 700 ScienceLeadR Reputation 3700

Unlock

Register Login
Network Map

Oncology

Subspecialties: Nuclear Medicine - Public Health - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Organizations

Source: Pubmed

Tokyo Metropolitan Komagome Hospital

Publications Synthesis

Source: Pubmed

Number : 1023

Citations

Citations: 46 577 1st author: 100 Last author: 374 Unique author: 17

Main journals

Cancer Res 127
Ann Oncol 70
Breast Cancer 62
J Clin Oncol 62
Gan To Kagaku Ryoho 42

Best Journals

Ann Oncol 32
J Clin Oncol 21
Lancet Oncol 19

Breakdown by type

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort.
breast neoplasms, neoplasms, pathology, biomarkers, breast, therapeutics		Mod Pathol20260
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.
autoantibodies, serum, breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics		Breast Cancer Res20260
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.
triple negative breast neoplasms, recombination, genetic, disease-free survival, homologous recombination, breast neoplasms, lymphocytes, neoplasms, drug therapy, aged, breast, therapeutics, chemotherapy		Breast Cancer Res Treat20260
Controlling Nutritional Status (CONUT) score as a key predictor of disability following conservative treatment of osteoporotic vertebral fractures.
hospitalization, conservative treatment, aged, osteoporosis, risk factors, nutritional status, therapeutics		Osteoporos Int20260
Response to the comment on "Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT".
radiotherapy, breast neoplasms, neoplasms, positron emission tomography computed tomography, breast		Ann Nucl Med20260

Clinical Studies 21

Source: ClinicalTrials

Synthesis

Principal Investigator: 2

By phase:

Phase 3 18
Phase 2 2
Phase 1/Phase 2 1

By status:

Completed 14
Active not recruiting 6
Recruiting 1

By type:

Interventional 21

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 17

Main Topics

Skin and Connective Tissue Diseases 20

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Trastuzumab Deruxtecan (T DXd) With or Without Pertuzumab Versus Taxane Trastuzumab and Pertuzumab in HER2 positive Metastatic Breast Cancer (DESTINY Breast09)
NCT04784715 — antineoplastic agents, phytogenic, breast neoplasms, docetaxel, paclitaxel, pharmaceutical preparations, antineoplastic agents, neoplasms, molecular mechanisms of pharmacological action, neoplasm metastasis, breast, infusions, intravenous, breast diseases, trastuzumab		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Source: Pubmed Source: ClinicalTrials